Report cover image

Myasthenia Gravis Treatment Market

Publisher Fortune Business Insights Pvt. Ltd.
Published Oct 01, 2024
Length 147 Pages
SKU # FOB19224224

Description

Myasthenia Gravis Treatment Market



Growth Factors of Myasthenia Gravis Treatment Market

The myasthenia gravis treatment market size was valued at USD 1.40 billion in 2023, and the market is now projected to grow from USD 1.51 billion in 2024 to USD 2.75 billion by 2032, exhibiting a CAGR of 7.8% during the forecast period of 2024-2032.

The COVID-19 effect posed as a disruptor on the myasthenia gravis treatment market growth because this posed a high level of risk to immune-compromised patients who received fewer admissions in the year 2020. However, relaxation on lockdowns and high vaccination rates in 2021 and 2022 remained the turning point for patient visits and thus marked a recovery in this market.

Increasing awareness of the treatment, rising diagnosis ratio and the geriatric population boost the myasthenia gravis treatment market share. The good reimbursement policies with new treatment requirements have shifted the pressure towards the key market participants to develop new drugs. Development in medical technology and research and better diagnosis with early treatment contribute to growth in the global market.

Furthermore, key players are working on new therapies for myasthenia gravis due to the side effects of traditional approaches and growing patient expectations. An increase in the diagnosis rates and patients wanting a cure, urge for new research and development of drugs. So the key players focus on subcutaneous Ig (SCIg) therapy, a new trend for the home healthcare requirements for patients with primary immune deficiency. The collaborations of companies and research institutions for the treatment are expanding the market.

Comprehensive Analysis of Myasthenia Gravis Treatment Market

This market expansion of the myasthenia gravis treatment and healthcare industry is useful for performing a detailed regional outlook based on the factors influencing pharmacy products' supply and demand. These segmentations are carefully segmented according to the drug class and distribution channel. The drug class includes, Cholinesterase Inhibitors, Corticosteroids, Immunosuppressants, IVIg and Monoclonal Antibodies. The distribution channel includes, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies.

North America is estimated to grow up to USD 0.69 billion in 2023 owing to the growing cases of myasthenia gravis and the population ageing. Advanced healthcare infrastructure and policies regarding reimbursement are enhancing diagnostic and therapeutic ratios. These factors are considered driving forces that sustain the market growth within the forecast period.

The leading market players have a significant presence in the healthcare industry ensuring industrial prospectus growth and the market trends. These players include, AstraZeneca (Cambridge, U.K.), Astellas Pharma Inc. (Tokyo, Japan), F. Hoffmann-La Roche Ltd. (Basel, Switzerland), Novartis AG (Basel, Switzerland), Veloxis Pharmaceuticals, Inc. (Horsholm, Denmark) and Bausch Health Companies Inc. (Laval, Canada). These market players provide a level-playing competitive landscape.

In October 2023, UCB S.A., a worldwide biopharmaceutical organization, declared that the ZILBRYSQ (zilucoplan) is approved in the USA for GMG and is among all adults, affecting those with anti-acetylcholine receptor (AChR) antibodies.

Segmentation Table

Global Myasthenia Gravis Treatment Market Scope

Study Period 2019-2032

Base Year 2023

Forecast Period 2024-2032

Growth Rate CAGR of 7.8% from 2024 to 2032

Historical Period 2019-2022

Unit Value (USD Billion)

Segmentation By Drug Class, Distribution Channel, and Region

By Drug Class
  • Cholinesterase Inhibitors
    • Corticosteroids
    • Immunosuppressants
    • IVIg
    • Monoclonal Antibodies
    By Distribution Channel
  • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    By Region
  • North America (By Drug Class, By Distribution Channel, and By Country)
    • U.S. (By Drug Class)
    • Canada (By Drug Class)
    • Europe (By Drug Class, By Distribution Channel, and By Country/Sub-region)
    • U.K. (By Drug Class)
    • Germany (By Drug Class)
    • France (By Drug Class)
    • Italy (By Drug Class)
    • Spain (By Drug Class)
    • Scandinavia (By Drug Class)
    • Rest of Europe (By Drug Class)
    • Asia Pacific (By Drug Class, By Distribution Channel, and By Country/Sub-region)
    • Japan (By Drug Class)
    • India (By Drug Class)
    • China (By Drug Class)
    • Australia (By Drug Class)
    • Rest of Asia Pacific (By Drug Class)
    • Rest of the World (By Drug Class, By Distribution Channel)


    Please Note: It will take 5-6 business days to complete the report upon order confirmation.

    Table of Contents

    147 Pages
    1. Introduction
    1.1. Research Scope
    1.2. Market Segmentation
    1.3. Research Methodology
    1.4. Definitions and Assumptions
    2. Executive Summary
    3. Market Dynamics
    3.1. Market Drivers
    3.2. Market Restraints
    3.3. Market Opportunities
    4. Key Insights
    4.1. Key Industry Developments (Mergers, Acquisitions, and Partnership)
    4.2. New Product Launches, by Key Players
    4.3. Impact of COVID-19 on the Market
    5. Global Myasthenia Gravis Treatment Market Analysis, Insights and Forecast, 2019-2032
    5.1. Market Analysis, Insights and Forecast – By Drug Class
    5.1.1. Cholinesterase Inhibitors
    5.1.2. Corticosteroids
    5.1.3. Immunosuppressants
    5.1.4. IVIg
    5.1.5. Monoclonal Antibodies
    5.2. Market Analysis, Insights and Forecast – By Distribution Channel
    5.2.1. Hospital Pharmacies
    5.2.2. Online Pharmacies
    5.2.3. Retail Pharmacies
    5.3. Market Analysis, Insights and Forecast – By Geography
    5.3.1. North America
    5.3.2. Europe
    5.3.3. Asia Pacific
    5.3.4. Rest of World
    6. North America Myasthenia Gravis Treatment Market Analysis, Insights and Forecast, 2019-2032
    6.1. Market Analysis, Insights and Forecast – By Drug Class
    6.1.1. Cholinesterase Inhibitors
    6.1.2. Corticosteroids
    6.1.3. Immunosuppressants
    6.1.4. IVIg
    6.1.5. Monoclonal Antibodies
    6.2. Market Analysis, Insights and Forecast – By Distribution Channel
    6.2.1. Hospital Pharmacies
    6.2.2. Online Pharmacies
    6.2.3. Retail Pharmacies
    6.3. Market Analysis, Insights and Forecast – By Country
    6.3.1. U.S.
    6.3.1.1. By Drug Class
    6.3.2. Canada
    6.3.2.1. By Drug Class
    7. Europe Myasthenia Gravis Treatment Market Analysis, Insights and Forecast, 2019-2032
    7.1. Market Analysis, Insights and Forecast – By Drug Class
    7.1.1. Cholinesterase Inhibitors
    7.1.2. Corticosteroids
    7.1.3. Immunosuppressants
    7.1.4. IVIg
    7.1.5. Monoclonal Antibodies
    7.2. Market Analysis, Insights and Forecast – By Distribution Channel
    7.2.1. Hospital Pharmacies
    7.2.2. Online Pharmacies
    7.2.3. Retail Pharmacies
    7.3. Market Analysis, Insights and Forecast – By Country/ Sub-region
    7.3.1. U.K.
    7.3.1.1. By Drug Class
    7.3.2. Germany
    7.3.2.1. By Drug Class
    7.3.3. France
    7.3.3.1. By Drug Class
    7.3.4. Spain
    7.3.4.1. By Drug Class
    7.3.5. Italy
    7.3.5.1. By Drug Class
    7.3.6. Scandinavia
    7.3.6.1. By Drug Class
    7.3.7. Rest of Europe
    7.3.7.1. By Drug Class
    8. Asia Pacific Myasthenia Gravis Treatment Market Analysis, Insights and Forecast, 2019-2032
    8.1. Market Analysis, Insights and Forecast – By Drug Class
    8.1.1. Cholinesterase Inhibitors
    8.1.2. Corticosteroids
    8.1.3. Immunosuppressants
    8.1.4. IVIg
    8.1.5. Monoclonal Antibodies
    8.2. Market Analysis, Insights and Forecast – By Distribution Channel
    8.2.1. Hospital Pharmacies
    8.2.2. Online Pharmacies
    8.2.3. Retail Pharmacies
    8.3. Market Analysis, Insights and Forecast – By Country/ Sub-region
    8.3.1. Japan
    8.3.1.1. By Drug Class
    8.3.2. China
    8.3.2.1. By Drug Class
    8.3.3. India
    8.3.3.1. By Drug Class
    8.3.4. Australia
    8.3.4.1. By Drug Class
    8.3.5. Rest of Asia Pacific
    8.3.5.1. By Drug Class
    9. Rest of World Myasthenia Gravis Treatment Market Analysis, Insights and Forecast, 2019-2032
    9.1. Market Analysis, Insights and Forecast – By Drug Class
    9.1.1. Cholinesterase Inhibitors
    9.1.2. Corticosteroids
    9.1.3. Immunosuppressants
    9.1.4. IVIg
    9.1.5. Monoclonal Antibodies
    9.2. Market Analysis, Insights and Forecast – By Distribution Channel
    9.2.1. Hospital Pharmacies
    9.2.2. Online Pharmacies
    9.2.3. Retail Pharmacies
    10. Competitive Analysis
    10.1. Global Market Share Analysis (2023)
    10.2. Company Profiles
    10.2.1. AstraZeneca
    10.2.1.1. Overview
    10.2.1.2. Products & Services
    10.2.1.3. SWOT Analysis
    10.2.1.4. Recent Developments
    10.2.1.5. Strategies
    10.2.1.6. Financials (Based on Availability)
    10.2.2. Astellas Pharma Inc.
    10.2.2.1. Overview
    10.2.2.2. Products & Services
    10.2.2.3. SWOT Analysis
    10.2.2.4. Recent Developments
    10.2.2.5. Strategies
    10.2.2.6. Financials (Based on Availability)
    10.2.3. F. Hoffmann-La Roche Ltd.
    10.2.3.1. Overview
    10.2.3.2. Products & Services
    10.2.3.3. SWOT Analysis
    10.2.3.4. Recent Developments
    10.2.3.5. Strategies
    10.2.3.6. Financials (Based on Availability)
    10.2.4. Novartis AG
    10.2.4.1. Overview
    10.2.4.2. Products & Services
    10.2.4.3. SWOT Analysis
    10.2.4.4. Recent Developments
    10.2.4.5. Strategies
    10.2.4.6. Financials (Based on Availability)
    10.2.5. Veloxis Pharmaceuticals, Inc.
    10.2.5.1. Overview
    10.2.5.2. Products & Services
    10.2.5.3. SWOT Analysis
    10.2.5.4. Recent Developments
    10.2.5.5. Strategies
    10.2.5.6. Financials (Based on Availability)
    10.2.6. Bausch Health Companies Inc.
    10.2.6.1. Overview
    10.2.6.2. Products & Services
    10.2.6.3. SWOT Analysis
    10.2.6.4. Recent Developments
    10.2.6.5. Strategies
    10.2.6.6. Financials (Based on Availability)

    Pricing

    Currency Rates
    How Do Licenses Work?

    How Do Licenses Work?

    The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

    • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

    • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

    • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

    • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

    • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

    License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

    Head shot

    Questions or Comments?

    Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
    Chat Now
    Contact Us